Related Experiment Video

Updated: Jul 6, 2026

Murine Oropharyngeal Aspiration Model of Ventilator-associated and Hospital-acquired Bacterial Pneumonia
04:32

Murine Oropharyngeal Aspiration Model of Ventilator-associated and Hospital-acquired Bacterial Pneumonia

Published on: June 28, 2018

Risk factors for treatment failure in patients with ventilator-associated pneumonia receiving appropriate antibiotic

Gul Gursel1, Muge Aydogdu, Ezgi Ozyilmaz

  • 1Department of Pulmonary Critical Care Medicine, Gazi University School of Medicine, Besevler, Ankara, Turkey. ggursel@gazi.edu.tr

Journal of Critical Care
|March 25, 2008
PubMed
Abstract

Insights

Patients with ventilator-associated pneumonia (VAP) who have comorbidities, are severely ill, and have low lymphocyte counts face a higher risk of treatment failure. Identifying these factors is crucial for improving VAP outcomes.

Area of Science:

  • Critical Care Medicine
  • Infectious Diseases
  • Pulmonology

Background:

  • Ventilator-associated pneumonia (VAP) is a significant cause of morbidity and mortality in intensive care units (ICUs).
  • Identifying predictors of treatment failure (TF) is essential for optimizing patient management and outcomes.

Purpose of the Study:

  • To investigate modifiable risk factors and predictors for treatment failure (TF) in patients with VAP receiving appropriate antibiotic therapy.
  • To identify patient, microbial, and ICU therapy-related factors associated with VAP treatment failure.

Main Methods:

  • An observational cohort study was conducted in a university hospital ICU.
  • Eighty-nine patients diagnosed with VAP were consecutively enrolled.
  • Treatment failure was defined as a lack of clinical and microbiological response within two weeks of therapy.

Main Results:

  • Fifty-three out of eighty-nine patients experienced treatment failure.
  • Independent predictors for TF included comorbidities (OR, 4.4), VAP-APACHE II scores >16 (OR, 6.4), low daily carbohydrate intake <190 g/d (OR, 3), and lymphocytopenia <1000/mm³ (OR, 4.1).
  • Patients with TF were older, had more comorbidities, higher APACHE II scores, and lower carbohydrate intake and lymphocyte counts.

Conclusions:

  • Severely ill patients with VAP, characterized by comorbidities and lymphocytopenia, are at a significantly higher risk for treatment failure.
  • These findings highlight the importance of early identification and management of these risk factors to improve VAP treatment success.

Related Concept Videos

Pneumonia IV: Management01:28

Pneumonia IV: Management

The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
Pneumonia I: Introduction01:29

Pneumonia I: Introduction

Pneumonia is an infection of the lower respiratory tract that leads to inflammation of the lung parenchyma, often resulting in the accumulation of inflammatory exudate in the alveoli and airways. Unlike the watery, low-protein fluid exudate in pulmonary edema, the exudate in this case is a thick fluid rich in immune cells, proteins, and debris produced during infection and inflammation.This impairs gas exchange and can lead to consolidation of lung tissue. The infection may be caused by a...
Pneumonia I: Introduction01:30

Pneumonia I: Introduction

Pneumonia is an acute respiratory infection that targets the lungs, specifically the alveoli. These tiny air sacs, essential for oxygen exchange, become engorged with pus and fluid, severely hindering breathing, decreasing oxygen absorption, and causing significant pain and discomfort during respiration.
Risk Factors
Various factors influence the likelihood of developing pneumonia. Age plays a crucial role, with infants, children under two, and individuals over 65 at increased risk due to their...
Pneumonia III: Complications and Assessment01:30

Pneumonia III: Complications and Assessment

Pneumonia poses the potential for numerous complications that warrant consideration. These complications include the following:
Mechanism of Antibiotic Resistance in MRSA01:25

Mechanism of Antibiotic Resistance in MRSA

Antibiotic resistance in bacteria arises when microorganisms evolve the ability to withstand drugs designed to kill them or inhibit their growth, rendering once-effective treatments useless. This phenomenon, driven by genetic change and selection under antibiotic exposure, poses a profound threat to modern medicine. Mechanisms include drug-inactivating enzymes (e.g., β-lactamases), efflux pumps that eject antibiotics, mutations altering antibiotic targets, decreased drug uptake, and acquisition...
Pneumonia V: Nursing management and Prevention01:30

Pneumonia V: Nursing management and Prevention

Nursing management of pneumonia involves promoting airway patency, facilitating rest and conserving energy, encouraging fluid intake, maintaining nutrition, and educating patients.
The nurse must practice strict medical asepsis and adhere to infection control guidelines to minimize healthcare-associated infections.
Enhance airway patency
Position the patient correctly to facilitate drainage of the affected lung segments. Manual or mechanical percussion and vibration can also be employed.